- SOHM recently acquired ABBIE, a world-class gene-editing platform capable of inserting larger DNA sequences, including full genes, into a desired location of the target cell’s genome
- ABBIE is poised to facilitate drug development, with SOHM confident that its new gene-editing technology can revolutionize the field of cardiology by supporting new ways of discovering and developing drugs
- The ABBIE platform system is easy to operate and boasts high efficiency, low cost, and simple design
- ABBIE improves on some of the shortcomings of CRISPR-Cas9 as well as other gene-editing technologies, such as enabling researchers to edit genes of a large number of cell types at different stages of their life cycles and does not require the cutting of double stranded DNA
- Compared to other gene-editing technologies, ABBIE has achieved significant strides in development with much less R&D spending
Genome editing refers to the modification of a cell’s DNA (genome) to block, improve, restore or add gene expression and gene function. It may be used to modify genomic DNA of a cell or subject to correct or to provide a model for a genetic disease. The process alters the expression of the gene and corrects the mutations or genetic differences that cause disease, thus modulating the disease, for instance. Gene editing is the direct result of advancements in human genomics, clinical medicine, molecular biology, and genetics, which have made it possible to directly target and modify genomic sequences of cells with clearly defined nuclei (eukaryotic cells), including human cells (https://ibn.fm/UHi7v).
Over the years, researchers have developed new gene-editing platforms and technologies, one of which was recently acquired by SOHM (OTC: SHMN), a pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs. SOHM acquired ABBIE, a world-class…
NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
